A first-in-man, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial to evaluate the safety, tolerability and pharmacokinetics of oral semaglutide in healthy males receiving oral semaglutide

Trial Profile

A first-in-man, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial to evaluate the safety, tolerability and pharmacokinetics of oral semaglutide in healthy males receiving oral semaglutide

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 18 Jul 2017 New trial record
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top